Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

Adam Zayac, MD, Andrew Matthew Evens, DO,MMSc, Andrzej Stadnik, MPH, BS, Stephen D. Smith, MD, Deepa Jagadeesh, MDMPH, Lori A. Leslie, MD, Catherine Wei, MD MA, Seo-Hyun Kim, MD, Seema Naik, MD, Suchitra Sundaram, MD, Nishitha Reddy, MD, Umar Farooq, MD, Vaishalee P. Kenkre, MD, Narendranath Epperla, MDMS, Kristie A. Blum, MD, Nadia Khan, MD, Daulath Singh, MD, Juan Pablo Alderuccio, MD, Amandeep Godara, MD, Maryam Yazdy, MD, Catherine Diefenbach, MD, Emma Rabinovich, MD, Gaurav Varma, MDMPH, Reem Karmali, MD, Yusra Shao, MD, Asaad Trabolsi, MD, Madelyn Burkart, MD, Peter Martin, FRCPC, MD MS, Sarah Stettner, Ayushi Chauhan, MBBS, Yun Kyong Choi, MD, Allandria Straker-Edwards, MS, Andreas Klein, MD, Michael C. Churnetski, Kirsten M Boughan, DO, Stephanie Berg, DO, Brad M. Haverkos, MDMPH,MS, Victor M. Orellana-Noia, MD, Christopher D'Angelo, MD, David A. Bond, MD, Seth M Maliske, MD, Ryan Vaca, MD, Gabriela Magarelli, APN, Amy Sperling, BS, Max J. Gordon, MD, Kevin A. David, MD, Paolo Caimi, MD, Manali Kamdar, MD, Craig A. Portell, MD, Parameswaran Venugopal, MD, Izidore S. Lossos, MD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 402.

https://doi.org/10.1182/blood-2019-122990

Published: 2019

Journal Articles

Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Amber C. King, PharmD, BCOP, Rachel Bolanos, PhD MPH, Kelly Velasco, PharmD, Huakang Tu, PhD, Faraz Zaman, MD, Mark B. Geyer, MD, Jae H. Park, MD

Blood (2019) 134 (Supplement_1): 5079.

https://doi.org/10.1182/blood-2019-122745

Published: 2019

Journal Articles

Early Mortality after Diagnosis of Diffuse Large B-Cell Lymphoma : A Retrospective, Single Urban-Community Hospital Study

Kunhwa Kim, MDMPH, Vinicius Machado Jorge, MD, Andrew Tiu, MD, Peter Mousaa, Sorab Gupta, MD, Djeneba Djibo, Claudia Dourado, MD

Blood (2019) 134 (Supplement_1): 5335.

https://doi.org/10.1182/blood-2019-132126

Published: 2019

Journal Articles

Optimize the Patient to Optimize the Therapy: Role of Prephase Cyclophosphamide in Aggressive Lymphoma

Nabin Karki, MBBS, Vamsi Kota, MBBS, Katherine Saunders, PharmD, Cara Iacobellis, PharmD, Anand Jillella, MD, Germame Ajebo, MD, Locke J. Bryan, MD

Blood (2019) 134 (Supplement_1): 5294.

https://doi.org/10.1182/blood-2019-129644

Published: 2019

Journal Articles

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Karl M. Kilgore, PhD, Iman Mohammadi, PhD, Amy Schroeder, BPharm, Christie Teigland, PhD, Anna Purdum, PharmD,MS, Gunjan L. Shah, MD

Blood (2019) 134 (Supplement_1): 793.

https://doi.org/10.1182/blood-2019-124364

Published: 2019

Journal Articles

Impact of Myeloproliferative Neoplasms (MPNs) on Health-Related Quality of Life (HRQOL) and Medical Resource Utilization: Results from the MERGE Registry

Ali Taher, MD PhD, Mohamed A Yassin, Zhijian Xiao, Hsin-An Hou, MD PhD, Tulin Tuglular, MD, Vikram Mathews, MD, Gerd Rippin, Islam Sadek, Asif Siddiqui, PhD, Raymond S Wong, MBChB, MD

Blood (2018) 132 (Supplement 1): 4311.

https://doi.org/10.1182/blood-2018-99-113248

Published: 2018

Journal Articles

End-of-Life Care Quality Outcomes Among Medicare Beneficiaries with Hematologic Malignancies

Pamela C Egan, MD, Thomas W. LeBlanc, MD MA, Adam J Olszewski, MD

Blood (2018) 132 (Supplement 1): 829.

https://doi.org/10.1182/blood-2018-99-112692

Published: 2018

Journal Articles

Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML

Yehuda E. Deutsch, MD, Justin T Presutto, PharmD, MBA, Amanda Brahim, Pharm.D., Jyotishankar Raychaudhuri, MD, Marco Andres Ruiz, MD, Jose Sandoval-Sus, MD, Hugo F. Fernandez, MD

Blood (2018) 132 (Supplement 1): 3559.

https://doi.org/10.1182/blood-2018-99-115682

Published: 2018

Journal Articles

Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients with Relapsed/Refractory (R/R) FLT3 -Mutated ( FLT3 mut ) and FLT3 -Wild Type ( FLT3 wt ) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study

James D. Griffin, MD, Manasee V Shah, MPH, Yan Song, PhD, Hongbo Yang, PhD

Blood (2018) 132 (Supplement 1): 4824.

https://doi.org/10.1182/blood-2018-99-110871

Published: 2018

Journal Articles

Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen

Robert M Rifkin, MD, Ralph V. Boccia, MD, Suman Kambhampati, MD, Joshua R Richter, MD, Saad Z Usmani, MD, Jack Aiello, EE, MS, BS, Brittany Sickler, BA, BS, Magdalena Schoeneich, MBA, MS, Bingxia Wang, PhD, Susan Zelt, PhD, Presley Whidden, MS, Lawrence E Dollar, PharmD, MS, Liviu Niculescu, MD, Stephen J Noga, MD

Blood (2017) 130 (Supplement 1): 5407.

https://doi.org/10.1182/blood.V130.Suppl_1.5407.5407

Published: 2017

Journal Articles

Effectiveness and Safety of Rivaroxaban in Patients with Cancer-Associated Venous Thromboembolism

Christine G. Kohn, BS, PharmD, Gary H. Lyman, MD MPH, FRCP, Jan Beyer-Westendorf, MD, Alex C. Spyropoulos, MD, Thomas J. Bunz, PharmD, PhD, Craig I. Coleman, PharmD

Blood (2017) 130 (Supplement 1): 3717.

https://doi.org/10.1182/blood.V130.Suppl_1.3717.3717

Published: 2017

Journal Articles

Managing Acute Myeloid Leukemia in Older Patients: Are We Making Progress? An Analysis of Treatment Patterns and Healthcare Resource Utilization

Marie-Hélène Lafeuille, MA, Murali Sundaram, MBA, PhD, Daniela Hoehn, MDPhD, Bruno Emond, MSc, Hela Romdhani, PhD, Patrick Lefebvre, MA

Blood (2017) 130 (Supplement 1): 4714.

https://doi.org/10.1182/blood.V130.Suppl_1.4714.4714

Published: 2017

Journal Articles

Racial Disparities in End-of-Life Care Planning and Hospital Utilization: A Single Center Retrospective Study

Kedar Kirtane, MD, Lois Downey, MA, Stephanie J. Lee, MD PhD, Jared Randall Curtis, MD MPH, Ruth Engelberg, PhD

Blood (2017) 130 (Supplement 1): 859.

https://doi.org/10.1182/blood.V130.Suppl_1.859.859

Published: 2017

Journal Articles

Transfusion Dependence and Use of Hospice Among Medicare Beneficiaries with Leukemia

Adam J Olszewski, MD, Pamela C Egan, MD, Thomas W. LeBlanc, MD MA

Blood (2017) 130 (Supplement 1): 277.

https://doi.org/10.1182/blood.V130.Suppl_1.277.277

Published: 2017

Journal Articles

Creation of Individualized Care Plans in High Risk Oncology Patients: A Team Based Model to Decrease Unnecessary Hospitalizations and ED Utilization

Girish Kunapareddy, MD, Joseph Hooley, MBA. CPPS, Pramod Pinnamaneni, MD, Leticia Varella, MD, Christa Poole, Helen Tackitt, Stacey Booker, Armida Parala, MD, Ruth Lagman, MD, Alberto J. Montero, MD MBA

Blood (2017) 130 (Supplement 1): 279.

https://doi.org/10.1182/blood.V130.Suppl_1.279.279

Published: 2017

Journal Articles

Real-World Outcomes of Ruxolitinib for Polycythemia Vera

Alexander Coltoff, MD, Douglas Tremblay, MD, Marina Kremyanskaya, MD PhD, Ronald Hoffman, MD, John Mascarenhas, MD

Blood (2017) 130 (Supplement 1): 2926.

https://doi.org/10.1182/blood.V130.Suppl_1.2926.2926

Published: 2017

Journal Articles

What Is the Cost of Disease Progression Among Patients with Indolent or Aggressive Non-Hodgkin Lymphoma (NHL)?

Nicole Engel-Nitz, PhD, Stacey Dacosta Byfield, PhD MPH, Timothy Bancroft, PhD, Anderson J. Amy, M.S., Carolina Reyes, PhD, May Chen, MD, Matthew J. Matasar, MD MS

Blood (2016) 128 (22): 5957.

https://doi.org/10.1182/blood.V128.22.5957.5957

Published: 2016

Journal Articles

Real-World Treatment Patterns, Health Care Utilization, and Costs Among Relapsed/ Refractory Multiple Myeloma (rrMM) Patients

Changxia Shao, PhD, Matthew Monberg, PhD, Xiting Cao, PhD, Wei Zhou, PhD, Yichen Zhong, MHS, Patricia Marinello, PharmD

Blood (2016) 128 (22): 3555.

https://doi.org/10.1182/blood.V128.22.3555.3555

Published: 2016

Journal Articles

When Should Patients Older Than 70 with Acute Myeloid Leukemia be Treated?

Jongphil Kim, Martine Extermann, MD PhD, Jeffrey E. Lancet, MD, Najla H Al Ali, Tea Reljic, MPH, Marina Sehovic, MD MPH, Varun C Dhulipala, MD, Benjamin Djulbegovic, MD PhD

Blood (2016) 128 (22): 4007.

https://doi.org/10.1182/blood.V128.22.4007.4007

Published: 2016

Journal Articles

Treatment of Venous Thromboembolism in Patients with Hematological Malignancies and Severe Thrombocytopenia: A Retrospective Cohort Analysis

Damon E. Houghton, MD, Jeffrey P. Laux, PhD, Nigel S. Key, MB, ChB, FRCP,, Neil A Zakai, MD MSc, Thomas C. Shea, MD, Stephan Moll, MD

Blood (2016) 128 (22): 531.

https://doi.org/10.1182/blood.V128.22.531.531

Published: 2016

NARROW

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Early Mortality after Diagnosis of Diffuse Large B-Cell Lymphoma : A Retrospective, Single Urban-Community Hospital Study

Optimize the Patient to Optimize the Therapy: Role of Prephase Cyclophosphamide in Aggressive Lymphoma

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Impact of Myeloproliferative Neoplasms (MPNs) on Health-Related Quality of Life (HRQOL) and Medical Resource Utilization: Results from the MERGE Registry

End-of-Life Care Quality Outcomes Among Medicare Beneficiaries with Hematologic Malignancies

Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML

Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients with Relapsed/Refractory (R/R) FLT3 -Mutated ( FLT3 mut ) and FLT3 -Wild Type ( FLT3 wt ) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study

Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen

Effectiveness and Safety of Rivaroxaban in Patients with Cancer-Associated Venous Thromboembolism

Managing Acute Myeloid Leukemia in Older Patients: Are We Making Progress? An Analysis of Treatment Patterns and Healthcare Resource Utilization

Racial Disparities in End-of-Life Care Planning and Hospital Utilization: A Single Center Retrospective Study

Transfusion Dependence and Use of Hospice Among Medicare Beneficiaries with Leukemia

Creation of Individualized Care Plans in High Risk Oncology Patients: A Team Based Model to Decrease Unnecessary Hospitalizations and ED Utilization

Real-World Outcomes of Ruxolitinib for Polycythemia Vera

What Is the Cost of Disease Progression Among Patients with Indolent or Aggressive Non-Hodgkin Lymphoma (NHL)?

Real-World Treatment Patterns, Health Care Utilization, and Costs Among Relapsed/ Refractory Multiple Myeloma (rrMM) Patients

When Should Patients Older Than 70 with Acute Myeloid Leukemia be Treated?

Treatment of Venous Thromboembolism in Patients with Hematological Malignancies and Severe Thrombocytopenia: A Retrospective Cohort Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only